These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32620236)

  • 1. Neutralization of HSF1 in cells from PIK3CA-related overgrowth spectrum patients blocks abnormal proliferation.
    Da Costa R; De Almeida S; Chevarin M; Hadj-Rabia S; Leclerc-Mercier S; Thauvin-Robinet C; Garrido C; Faivre L; Vabres P; Duplomb L; Jego G
    Biochem Biophys Res Commun; 2020 Sep; 530(3):520-526. PubMed ID: 32620236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
    Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
    Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
    Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
    Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causal somatic mutations in urine DNA from persons with the CLOVES subgroup of the PIK3CA-related overgrowth spectrum.
    Michel ME; Konczyk DJ; Yeung KS; Murillo R; Vivero MP; Hall AM; Zurakowski D; Adams D; Gupta A; Huang AY; Chung BHY; Warman ML
    Clin Genet; 2018 May; 93(5):1075-1080. PubMed ID: 29231959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS).
    Martinez-Lopez A; Blasco-Morente G; Perez-Lopez I; Herrera-Garcia JD; Luque-Valenzuela M; Sanchez-Cano D; Lopez-Gutierrez JC; Ruiz-Villaverde R; Tercedor-Sanchez J
    Clin Genet; 2017 Jan; 91(1):14-21. PubMed ID: 27426476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS).
    Vahidnezhad H; Youssefian L; Uitto J
    Exp Dermatol; 2016 Jan; 25(1):17-9. PubMed ID: 26268729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
    Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
    Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes.
    Emrick LT; Murphy L; Shamshirsaz AA; Ruano R; Cassady CI; Liu L; Chang F; Sutton VR; Li M; Van den Veyver IB
    Am J Med Genet A; 2014 Oct; 164A(10):2633-7. PubMed ID: 25044986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy in patients with PIK3CA-related overgrowth syndrome.
    Venot Q; Blanc T; Rabia SH; Berteloot L; Ladraa S; Duong JP; Blanc E; Johnson SC; Hoguin C; Boccara O; Sarnacki S; Boddaert N; Pannier S; Martinez F; Magassa S; Yamaguchi J; Knebelmann B; Merville P; Grenier N; Joly D; Cormier-Daire V; Michot C; Bole-Feysot C; Picard A; Soupre V; Lyonnet S; Sadoine J; Slimani L; Chaussain C; Laroche-Raynaud C; Guibaud L; Broissand C; Amiel J; Legendre C; Terzi F; Canaud G
    Nature; 2018 Jun; 558(7711):540-546. PubMed ID: 29899452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular diagnosis of somatic overgrowth conditions: A single-center experience.
    Lalonde E; Ebrahimzadeh J; Rafferty K; Richards-Yutz J; Grant R; Toorens E; Marie Rosado J; Schindewolf E; Ganguly T; Kalish JM; Deardorff MA; Ganguly A
    Mol Genet Genomic Med; 2019 Mar; 7(3):e536. PubMed ID: 30761771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic heterogeneity in PIK3CA-related overgrowth spectrum.
    Vahidnezhad H; Youssefian L; Baghdadi T; Sotoudeh S; Tavassoli A; Zeinali S; Afsharaalam S; Uitto J
    Br J Dermatol; 2016 Oct; 175(4):810-4. PubMed ID: 27037860
    [No Abstract]   [Full Text] [Related]  

  • 12. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum: A brief report.
    Denorme P; Morren MA; Hollants S; Spaepen M; Suaer K; Zutterman N; Labarque V; Legius E; Brems H
    Pediatr Dermatol; 2018 May; 35(3):e186-e188. PubMed ID: 29493003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
    Keppler-Noreuil KM; Sapp JC; Lindhurst MJ; Parker VE; Blumhorst C; Darling T; Tosi LL; Huson SM; Whitehouse RW; Jakkula E; Grant I; Balasubramanian M; Chandler KE; Fraser JL; Gucev Z; Crow YJ; Brennan LM; Clark R; Sellars EA; Pena LD; Krishnamurty V; Shuen A; Braverman N; Cunningham ML; Sutton VR; Tasic V; Graham JM; Geer J; Henderson A; Semple RK; Biesecker LG
    Am J Med Genet A; 2014 Jul; 164A(7):1713-33. PubMed ID: 24782230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway.
    Akgumus G; Chang F; Li MM
    J Mol Diagn; 2017 Jul; 19(4):487-497. PubMed ID: 28502730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum.
    Yeung KS; Ip JJ; Chow CP; Kuong EY; Tam PK; Chan GC; Chung BH
    Am J Med Genet A; 2017 Apr; 173(4):978-984. PubMed ID: 28328134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of congenital lipomatous overgrowth, vascular malformations, epidermal nevi, spinal/skeletal anomalies and/or scoliosis syndrome with lipoatrophy as an important clinical manifestation.
    Schreiber A; Grenier PO; Auger I
    Pediatr Dermatol; 2017 Nov; 34(6):735-736. PubMed ID: 28833506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PIK3CA-related overgrowth syndrome (PROS)].
    Venot Q; Canaud G
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Diagnosis of Mosaic Overgrowth Syndromes Using a Custom-Designed Next-Generation Sequencing Panel.
    Chang F; Liu L; Fang E; Zhang G; Chen T; Cao K; Li Y; Li MM
    J Mol Diagn; 2017 Jul; 19(4):613-624. PubMed ID: 28502725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors.
    Loconte DC; Grossi V; Bozzao C; Forte G; Bagnulo R; Stella A; Lastella P; Cutrone M; Benedicenti F; Susca FC; Patruno M; Varvara D; Germani A; Chessa L; Laforgia N; Tenconi R; Simone C; Resta N
    PLoS One; 2015; 10(4):e0123092. PubMed ID: 25915946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpelisib Treatment for Genital Vascular Malformation in a Patient with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) Syndrome.
    López Gutiérrez JC; Lizarraga R; Delgado C; Martínez Urrutia MJ; Díaz M; Miguel M; Triana P
    J Pediatr Adolesc Gynecol; 2019 Dec; 32(6):648-650. PubMed ID: 31330249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.